U.S. Markets open in 6 hrs 26 mins
  • S&P Futures

    4,406.25
    -8.00 (-0.18%)
     
  • Dow Futures

    34,956.00
    -78.00 (-0.22%)
     
  • Nasdaq Futures

    15,100.50
    -17.25 (-0.11%)
     
  • Russell 2000 Futures

    2,203.40
    -10.00 (-0.45%)
     
  • Crude Oil

    71.90
    -0.01 (-0.01%)
     
  • Gold

    1,794.10
    -5.10 (-0.28%)
     
  • Silver

    25.23
    -0.09 (-0.35%)
     
  • EUR/USD

    1.1791
    -0.0017 (-0.1415%)
     
  • 10-Yr Bond

    1.2760
    0.0000 (0.00%)
     
  • Vix

    17.58
    +0.38 (+2.21%)
     
  • GBP/USD

    1.3807
    -0.0017 (-0.1201%)
     
  • USD/JPY

    110.1470
    -0.2280 (-0.2066%)
     
  • BTC-USD

    37,068.00
    -1,616.20 (-4.18%)
     
  • CMC Crypto 200

    878.40
    -37.08 (-4.05%)
     
  • FTSE 100

    7,025.43
    0.00 (0.00%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

Teva's Crash Is Just Getting Started, Here Comes a 55% Bear Raid

Share of Teva Pharmaceutical have not done very well lately, with shares tumbling more than 30% over the past two trading days. TEVA stock is now down 43% since the start of 2017, hitting its lowest levels since 2003.

The trouble began when Teva reported its second-quarter earnings. Although sales grew 13%, earnings plunged and cash flows dried up. As a result, management cut guidance. Then the analysts piled on. Monday isn't getting much better, with Teva stock down 4% one hour into the session.

Analysts at the Bank of Jerusalem downgraded Teva to market perform and assigned a $26 price target -- $6 per share higher than its current price. However, Morgan Stanley downgraded the stock to underweight and assigned a $16 price target. The target implies about $4 per share or 20% more downside from current levels.

That's analyst David Risinger's best-case scenario, who used to have a $36 price target on it. Pricing pressure on generic drugs should continue, weighing on Teva earnings, he reasoned. As a result, Risinger cut his EPS forecast for fiscal 2017, 2018 and 2019.

Risinger's bear case is far more stark, with a price target of just $9. The bear case price target factors in an even worse-than-anticipated decline in Teva's business. Risinger's $9 price target would imply $11 per share of downside, or another 55%. Ouch.

It doesn't help that there have also been concerns about its debt load, too.

More of What's Trending on TheStreet:

EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potentially HUGE winners. Click here to see his holdings for FREE.